South Korea Tops Asia Pacific Pharmaceuticals & Healthcare BERs For Q310

Japan is no longer the most attractive pharmaceutical market in Asia Pacific, according to BMI's Q310 Pharmaceuticals & Healthcare Business Environment Ratings (BERs) for the region. Prospects for medicines sales have deteriorated slightly and our Country Risk team's assessment of Japan's economic structure has become more negative. This has resulted in the country's Pharmaceuticals & Healthcare BER score falling from 68.2 out of 100 in Q210 to 66.7 in

To read the full article, please choose one of the following options: